Bronchodilator responsiveness using spirometry in healthy and asthmatic preschool children
- Luis Miguel Borrego1,4,
- Janet Stocks2,
- Isabel Almeida1,
- Sanja Stanojevic2,3,
- João Antunes1,
- Paula Leiria-Pinto1,
- José E Rosado-Pinto1,
- Ah-Fong Hoo2
- 1Serviço de Imunoalergologia, Centro Hospitalar Lisboa Central—Hospital de Dona Estefania, Lisboa, Portugal
- 2Portex Respiratory Unit, UCL Institute of Child Health & Great Ormond Street Hospital NHS Foundation Trust, London, UK
- 3Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Canada
- 4CEDOC, Department of Immunology, Faculty of Medical Sciences, Universidade Nova de Lisboa, Portugal
- Correspondence to Professor Dr Luis Miguel Borrego, Departamento de Imunologia, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Campo dos Mártires da Pátria 123, Lisboa 1150–227, Portugal;
- Received 9 February 2012
- Revised 1 October 2012
- Accepted 27 November 2012
- Published Online First 3 January 2013
Objective To assess repeatability and reproducibility of spirometry measurements, and bronchodilator responsiveness (BDR), in healthy 3–6-year-old preschool children and those with asthma.
Design Spirometry was performed before and 20 minutes after administering either inhaled placebo (for repeatability) or 400 μg salbutamol (for BDR) on two separate occasions (reproducibility) 3–23 days apart in asthmatic preschoolers and healthy controls.
Settings Lung Function Laboratory, Hospital de Dona Estefania, Lisbon.
Participants Healthy preschool children and those with physician-diagnosed asthma, recruited from local Health Clinics and Outpatient Clinic.
Main outcome measures Paired measurements of forced expired volume in 0.75 s (FEV0.75) and forced mid-expiratory flows (FEF25–75).
Results Technically successful baseline results were obtained in 86% of children assessed. Paired data were obtained in 43 asthmatic and 22 controls (median (range) age: 5.1 (3.4–6.8) years). Baseline FEV0.75 was significantly lower in asthmatic children (mean (SD): 90 (15)% predicted) than in controls (102 (13) % predicted; p<0.001). Within-occasion coefficient of repeatability following placebo was similar in both groups, being 10.4% in asthma and 13.2% in controls for FEV0.75. Following bronchodilator, FEV0.75 increased significantly more in asthmatic preschoolers (mean (SD): 15.0 (12) %) than in controls (4.5 (5) %; p<0.001), with no significant difference between groups post-bronchodilator. Between-occasion variability was similar to within-day repeatability in controls, but almost twice as high in asthmatic children.
Conclusions BDR can be assessed reliably using FEV0.75 in wheezy preschoolers, provided within-subject variability and responsiveness in health are taken into consideration.